Product Feature

Platelet-Rich Plasma (PRP) regenerative therapy extracts high-concentration growth factors from the patient's own blood to reduce inflammation, relieve pain, and accelerate tissue regeneration.

PoroGraft® bone graft features a calcium-phosphorus ratio and zinc-magnesium ion content highly similar to human bone, efficiently regulating cell behavior, rapidly adsorbing bioactive substances, promoting cell migration and differentiation, and inducing bone regeneration.

PoroGraft® oral bone graft features excellent hydrophilicity and clumping properties, with purity exceeding 95% and no post-surgical rejection. Sourced from natural porcine femoral metaphyseal cancellous bone with a calcium-phosphorus ratio similar to human bone.

PoroGraft® bone graft is sourced from natural porcine femoral metaphyseal cancellous bone, with only 20-40g extractable per pig. Its intact natural microporous structure, rougher surface area, and higher zinc-magnesium content provide an ideal scaffold for oral bone regeneration.

PoroGraft® represents a new direction for oral bone grafting in China, featuring premium natural porcine cancellous bone, gradient temperature-rising calcination for high-purity quality, and calcium-phosphorus ratio with zinc-magnesium content similar to human bone for efficient bone regeneration.

The Medgen PRP Preparation Device features a three-chamber integrated design, optimized two-step centrifugation, and three patented safety technologies, achieving 4.3-6.8x platelet concentration with >99% red blood cell removal rate.

After 8 years of independent R&D, Medgen Life Science's three core products — BoneSwift™ injectable bone graft, PoroGraft® oral bone filler, and PRP preparation device — have all received NMPA Class III medical device certification, with multiple technologies filling domestic market gaps.

Medgen Life Science's independently developed first domestic pre-filled injectable bone graft has completed clinical trial follow-ups across three centers, marking a major milestone in the company's bone filling material development and a significant step toward commercialization.